DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Mecasermin Tercica.

Author(s): Norman P

Affiliation(s): Norman Consulting, 18 Pink Lane, Burnham, Bucks, UK. peter.norman2@btinternet.com

Publication date & source: 2006-04, Curr Opin Investig Drugs., 7(4):371-80.

Publication type: Review

Tercica, under license from Genentech, has developed and launched mecasermin, recombinant human insulin-like growth factor-1 (rhIGF-1), for the treatment of growth failure in children with primary IGF deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.

Page last updated: 2007-05-02

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017